Youngevity International Inc (NASDAQ:YGYI) Director Paul Sallwasser sold 5,140 shares of Youngevity International stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $5.04, for a total value of $25,905.60. Following the transaction, the director now directly owns 62,853 shares in the company, valued at $316,779.12. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

YGYI traded up $0.12 during midday trading on Wednesday, hitting $5.13. 2,528 shares of the company were exchanged, compared to its average volume of 161,372. Youngevity International Inc has a 1-year low of $3.17 and a 1-year high of $16.25. The company has a quick ratio of 0.49, a current ratio of 1.16 and a debt-to-equity ratio of 0.53.

Youngevity International (NASDAQ:YGYI) last announced its earnings results on Tuesday, April 16th. The company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.40). The company had revenue of $36.11 million for the quarter. Youngevity International had a negative return on equity of 125.30% and a negative net margin of 17.08%.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its holdings in Youngevity International by 83.8% during the 1st quarter. BlackRock Inc. now owns 23,778 shares of the company’s stock worth $135,000 after buying an additional 10,840 shares during the period. Jefferies Group LLC acquired a new position in Youngevity International during the 1st quarter worth about $68,000. ExodusPoint Capital Management LP bought a new position in shares of Youngevity International in the 1st quarter worth about $87,000. Citigroup Inc. bought a new position in shares of Youngevity International in the 1st quarter worth about $88,000. Finally, Northern Trust Corp bought a new position in shares of Youngevity International in the 4th quarter worth about $96,000. 4.59% of the stock is currently owned by hedge funds and other institutional investors.

Separately, Benchmark lifted their target price on Youngevity International from $9.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, February 13th.

WARNING: This report was originally reported by Marea Informative and is the property of of Marea Informative. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at

About Youngevity International

Youngevity International, Inc develops and distributes health and nutrition related products and services through independent direct selling network in the United States and internationally. It operates in two segments, Direct Selling and Commercial Coffee. The company offers approximately 5,500 products, including nutritional, vitamin, mineral, herbal, liquid, and dietary supplements; apparel; fashion and jewelry accessories; digital products; and packaged foods.

Featured Story: Gap Up Stocks

Receive News & Ratings for Youngevity International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Youngevity International and related companies with's FREE daily email newsletter.